Ascendis Pharma
Founded in Copenhagen, Denmark in 2007, Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our innovative TransCon™ technology platform to create new and potentially best-in-class therapies.
Today, we’re advancing programs in Endocrinology Rare Disease, Oncology, and Ophthalmology. We currently have five product candidates in clinical development: three in Endocrinology Rare Disease and two in Oncology. In addition, Ascendis recently announced new pre-clinical programs in Ophthalmology.
We are a dynamic, growing biopharma company with headquarters in Copenhagen and additional offices and research facilities in Germany (Heidelberg, Munich, and Berlin) and the United States (Palo Alto, California, and Princeton, New Jersey).